K. Parsons

Targeted Therapies for Triple-Negative Breast Cancer: Combating a Stubborn Disease.

Sriganesh Srihari, Kum Kum Khanna, Deepak Mittal, 2015, Trends in pharmacological sciences.

Superior in vivo efficacy of afucosylated trastuzumab in the treatment of HER2-amplified breast cancer.

M. Sliwkowski, R. Kelley, K. Parsons, 2010, Cancer research.

Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate.

John M Lambert, Wai Lee T Wong, Guangmin Li, 2008, Cancer research.

Clinical Cancer esearch cer Therapy : Preclinical ineered Thio-Trastuzumab-DM 1 Conjugate with an roved Therapeutic Index to Target Human Epidermal R wth Factor Receptor 2 – Positive Breast Cancer

S. Spencer, P. Polakis, K. Parsons, 2010 .